Inequalities, harm reduction and non-combustible nicotine products: a meta-ethnography of qualitative evidence.
TL;DR: Qualitative evidence on how smokers in different socioeconomic groups engage with non-combustible nicotine products, including electronic cigarettes and nicotine replacement therapies, is reviewed in order to provide insight into how these products might impact on smoking inequalities.
read more
Abstract: We sought to review qualitative evidence on how smokers in different socioeconomic groups engage with non-combustible nicotine products (NCNP), including electronic cigarettes and nicotine replacement therapies, in order to provide insight into how these products might impact on smoking inequalities. We searched ten electronic databases in February 2017 using terms relating to NCNP and socioeconomic status. We included qualitative studies that were published since 1980 and were available in English. We used guidelines adapted from the Critical Appraisal Skills Programme for appraising qualitative research. The review only identified studies exploring the attitudes of socioeconomically disadvantaged smokers towards NCNP for harm reduction or cessation purposes (i.e. we did not identify any relevant studies of more advantaged socioeconomic groups). Using a lines-of-argument meta-ethnographic approach, we identified a predominantly pessimistic attitude to NCNP for harm reduction or cessation of smoking due to: wider circumstances of socioeconomic disadvantage; lack of a perceived advantage of alternative products over smoking; and a perceived lack of information about relative harms of NCNP compared to smoking. Optimistic findings, although fewer, suggested the potential of NCNP being taken up among smokers experiencing socioeconomic disadvantage. Overall, our review highlights the importance of considering the social, cultural and economic circumstances that influence experiences of smoking and of alternative product use.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Perceived efficacy of e-cigarettes versus nicotine replacement therapies among successful e-cigarette users – a qualitative approach
Amanda Barbeau
- 05 Nov 2013
TL;DR: These findings suggest tobacco control practitioners must pay increased attention to the importance of the behavioral and social components of smoking addiction by addressing these components in addition to nicotine dependence, e-cigarettes appear to help some tobacco smokers transition to a less harmful replacement tool, thereby maintaining cigarette abstinence.
168
A scoping review on disparities in exposure to advertising for e-cigarettes and heated tobacco products and implications for advancing a health equity research agenda.
TL;DR: In this paper, the authors identified potential disparities in exposure to e-cigarette and heated tobacco product (HTP) advertising and promotion across populations and identified causal relationships that underlie disparities.
Socio-economic distribution of e-cigarette use among recent former regular smokers and current smokers at ages 25-26 in England.
Thierry Gagné,Jamie Brown +1 more
TL;DR: Among young adult smokers in England, lower‐status occupational groups were more likely to use e‐cigarettes on a non‐daily basis than to have never used compared with higher status occupational groups.
Reducing lifestyle risk behaviours in disadvantaged groups in high-income countries: A scoping review of systematic reviews
TL;DR: This article identified and brought together systematic reviews with a focus on reducing risk behaviours in disadvantaged groups and highlighted where evidence is lacking, and identified gaps in the evidence for care leavers; Gypsies, Travellers, and Roma and limited evidence for refugees and unemployed people.
Nicotine pouch pharmacokinetics compared to smoked tobacco: A systematic review and meta-analysis
Javad Heshmati,Spencer Shahen,Sarah Visintini,Evyanne Quirouette,Kerri-Anne Mullen,Hassan Mir +5 more
Abstract: Nicotine pouches (NP) are novel agents that deliver nicotine through buccal absorption as opposed to combustion. They are proposed as a harm reduction tool compared to smoking tobacco. However, there is limited evidence on their efficacy and safety. This review article summarizes the current evidence regarding NP pharmacokinetics compared to conventional tobacco products. We searched Medline, Embase, CENTRAL and Scopus for studies that assessed pharmacokinetic parameters of nicotine pouches. We identified studies involving tobacco-dependent adults and examined pharmacokinetic parameters such as total exposure, peak concentration, and time to peak. A meta-analysis was conducted using random-effects models to calculate pooled effect sizes. The Cochrane ROB 2.0 tool was used to evaluate the risk of bias in the included studies. A total of seven RCTs and crossover trials were included. Five compared NP pharmacokinetics with smoked tobacco, while two used moist snuff as comparators. Total nicotine exposure was significantly lower with 1.5 mg and 2 mg pouches, similar with 3.5 mg and 4 mg pouches, and significantly higher with pouches containing 8 mg or more when compared to cigarettes. A meta-analysis of three trials showed that 4 mg pouches delivered 91.73 % (95 % CI 85.03 %–98.42 %) of cigarette total nicotine exposure. Peak concentration was significantly lower with 1.5 mg, 2 mg, and 3.5 mg pouches while higher concentration pouches had greater peak when compared to cigarettes. A meta-analysis of three trials showed that 4 mg pouches showed a peak nicotine concentration of 69.15 % (95 % CI 58.55 %–79.76 %) compared with cigarettes. Peak nicotine concentration was consistently achieved earlier with cigarettes (5–8 min) than with pouches (20–65 min). Despite their buccal absorption, 4 mg pouches (most commonly used), deliver similar total nicotine exposure to cigarettes, though with lower peak concentrations and slower absorption. When combined with their flavours and aggressive marketing to youth, this raises concerns about the potential of nicotine pouches to cause nicotine dependence, especially among those using the product recreationally.
References
Histories of harm reduction: illicit drugs, tobacco, and nicotine.
TL;DR: This paper traces the different historical routes which the public health concept of "harm reduction" has taken for illicit drugs and for tobacco and nicotine and identifies institutional and cultural/conceptual planes for discussion.
Barriers and motivators to gaining access to smoking cessation services amongst deprived smokers – a qualitative study
TL;DR: It is concluded that smokers from the most socio-economically deprived areas of Nottingham UK generally had low awareness of the services available to help them, and misconceptions about their availability and effectiveness.
Contribution of smoking to socioeconomic inequalities in mortality: a study of 14 European countries, 1990–2004
G Gregoraci,G Gregoraci,F.J. van Lenthe,Barbara Artnik,Matthias Bopp,P Deboosere,Katalin Kovács,Cwn Looman,Pekka Martikainen,Gwenn Menvielle,Frederik Peters,Bogdan Wojtyniak,R de Gelder,Johan P. Mackenbach +13 more
TL;DR: Since 1990–1994, absolute inequalities in smoking-attributable mortality and the contribution of smoking to inequalities in total mortality have decreased in most countries among men, but increased among women, and in many European countries, smoking has become less important as a determinant of socioeconomic inequalities in mortality among men.
Everyday tactics in local moral worlds: E-cigarette practices in a working-class area of the UK.
TL;DR: E-cigarettes did have some potential to overcome normative barriers to smoking cessation and therefore to reduce health inequalities, at least in relation to male smoking, and Kleinman's local moral worlds are drawn to make sense of these findings.
Expenditure on smoking and alternative nicotine delivery products: a population survey in England.
TL;DR: In England, expenditure among e-cigarette and nicotine replacement therapy (NRT) users is approximately one third of the expenditure of smokers, although this is likely to differ according to individual usage patterns.